GlassScriptPhysician profile
Gabruce A Young
NPI 1184647992
$9,652.71
in general payments reported to CMS, 2019-2025
51 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,738 · 2020: $898 · 2021: $708 · 2022: $1,161 · 2023: $1,650 · 2024: $1,742 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,090 · Education: $57.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,089.51 |
| Education | $57.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,266.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $961.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $829.47 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $808.09 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $640.38 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $540.74 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $511.43 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $503.70 | 2019-2025 | Repatha, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $388.40 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.45 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $343.56 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.64 | 2019-2025 | Jardiance, Tradjenta |
| Corium, LLC | $184.83 | 2023-2024 | Azstarys |
| Abbott Laboratories | $170.64 | 2022-2023 | Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $161.04 | 2024-2025 | Voquezna |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabruce Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.